EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC.OB), a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that it has begun the launch of LAVIV™ (azficel-T) in major metropolitan areas throughout the U.S. LAVIV is a revolutionary treatment for “smile line” wrinkles made from a person’s own skin cells and was approved by the FDA on June 21, 2011 as the first and only personalized cell therapy for use in aesthetics. LAVIV was recently named a 2011 Allure Best of Beauty Award winner in the magazine’s annual cover story (October 2011 issue).
